Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments beta cell mass via activation of beta cell proliferation and islet neogenesis. We examined whether GLP-1 receptor signaling modifies the cellular susceptibility to apoptosis. Mice administered streptozotocin (STZ), an agent known to induce beta cell apoptosis, exhibit sustained improvement in glycemic control and increased levels of plasma insulin with concomitant administration of the GLP-1 agonist exendin-4 (Ex-4). Blood glucose remained significantly lower for weeks after cessation of exendin-4. STZ induced beta cell apoptosis, which was significantly reduced by co-administration of Ex-4. Conversely, mice with a targeted disruption of the GLP-1 receptor gene exhibited increased beta cell apoptosis after STZ administration. Exendin-4 directly reduced cytokine-induced apoptosis in purified rat beta cells exposed to interleukin 1beta, tumor necrosis fator alpha, and interferon gamma in vitro. Furthermore, Ex-4-treated BHK-GLP-1R cells exhibited significantly increased cell viability, reduced caspase activity, and decreased cleavage of beta-catenin after treatment with cycloheximide in vitro. These findings demonstrate that GLP-1 receptor signaling directly modifies the susceptibility to apoptotic injury, and provides a new potential mechanism linking GLP-1 receptor activation to preservation or enhancement of beta cell mass in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [19]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Self-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Induction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Self-citationDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationSherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0414 · Cited by 726
Research works printed but not linked: 7
- de la Tour, 2001, Mol. Endocrinol., 15, 476
- Boushey, 2001, Cancer Res., 61, 687
- Trumper, 2001, Mol. Endocrinol., 15, 1559
- Drucker, 1997, Am. J. Physiol., 273, G1252
- Drucker, 2001, J. Clin. Endocrinol. Metab., 86, 1759
- Bregenholt, 2001, 50, 125
- Sherwood, 2000, Endocr. Rev., 21, 619
Cited by
Items 201–300 of 597
Interventions to Preserve Beta-Cell Function in the Management and Prevention of Type 2 Diabetes
Page, K. A., & Reisman, T. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0363-2 · Cited by 65
“Studies in animals have shown the GLP-1 analogues decrease β-cell apoptosis and increase β-cell mass [63–65], and human studies indicate that exenatide exerts potent anti-inflammatory effects that are independent of weight loss [66].”
Gastrointestinal hormones and the regulation of β‐cell mass
Lavine, J. A., & Attie, A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05802.x · Cited by 63
Hamamoto, S., Kanda, Y., Shimoda, M., Tatsumi, F., Kohara, K., Tawaramoto, K., Hashiramoto, M., & Kaku, K. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12005 · Cited by 67
Zhu, B., Gong, N., Fan, H. J., Peng, C., Ding, X., Jiang, Y., & Wang, Y. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000320 · Cited by 61
Koehler, J. A., & Drucker, D. J. (2006) · Diabetes · doi:10.2337/db05-1145 · Cited by 60
Self-citationIslet cell plasticity and regeneration
Migliorini, A., Bader, E., & Lickert, H. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.010 · Cited by 71
“They also trigger activation of pro-survival and anti-apoptotic pathways in pancreatic β-cells [70,71].”
BackgroundJun, L. S., Millican, R. L., Hawkins, E. D., Konkol, D. L., Showalter, A. D., Christe, M. E., Michael, M. D., & Sloop, K. W. (2015) · Diabetes · doi:10.2337/db14-1052 · Cited by 60
Herbach, N., Göke, B., Schneider, M. R., Hermanns, W., Wolf, E., & Wanke, R. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.021 · Cited by 70
Aston-Mourney, K., Hull, R. L., Zraika, S., Udayasankar, J., Subramanian, S. L., & Kahn, S. E. (2011) · Diabetologia · doi:10.1007/s00125-011-2143-3 · Cited by 56
“As exendin-4 is well documented to have anti-apoptotic effects in mouse islets [19, 41, 42], and we demonstrated that exendin-4 treatment resulted in increased AKT activation, this was somewhat surprising.”
Glucose‐dependent insulinotropic polypeptide signaling in pancreatic β‐cells and adipocytes
McIntosh, C. H., Widenmaier, S., & Kim, S. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00196.x · Cited by 57
The role of the Wnt signaling pathway in incretin hormone production and function
Chiang, Y., Ip, W., & Jin, T. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00273 · Cited by 65
“Additional pancreatic effects of GLP-1 include the sensitization of β-cells to glucose, as well as the induction of proliferation and neogenesis of β-cells (Xu et al., 1999; Tourrel et al., 2001; Li et al., 2003).”
BackgroundFujita, Y., Chui, J. W. Y., King, D. S., Zhang, T., Seufert, J., Pownall, S., Cheung, A. T., & Kieffer, T. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90440.2008 · Cited by 59
“Thus, in mice where GIP or GLP-1 receptor expression is disrupted, glucose tolerance is impaired and sensitivity to -cell injury is increased (27, 29, 33).”
BackgroundKai, A. K. L., Lam, A. K. M., Chen, Y., Tai, A. C. P., Zhang, X., Lai, A. K. W., Yeung, P. K. K., Tam, S., Wang, J., Lam, K. S., et al. (2013) · The FASEB Journal · doi:10.1096/fj.13-230433 · Cited by 58
Glucagon Receptor Signaling Is Essential for Control of Murine Hepatocyte Survival
Sinclair, E. M., Yusta, B., Streutker, C., Baggio, L. L., Koehler, J. A., Charron, M. J., & Drucker, D. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.075 · Cited by 58
Self-citationβ-Cell preservation with thiazolidinediones
Campbell, I. W., & Mariz, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.08.015 · Cited by 63
Figueiredo, C. P., Pamplona, F. A., Mazzuco, T. L., Aguiar, A. S., Walz, R., & Prediger, R. D. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833c8544 · Cited by 62
“…their novel enzymeresistant analogs (N-AcGIP and exendin-4, EX-4, respectively) induce numerous biological actions in the pancreas, including glucose homeostasis regulation, insulin release, and, notably, b-cell proliferation and inhibition of apoptosis (Li et al., 2003; Baggio and Drucker, 2007).”
BackgroundInfluentialYoshida, S., Tanaka, H., Oshima, H., Yamazaki, T., Yonetoku, Y., Ohishi, T., Matsui, T., & Shibasaki, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.141 · Cited by 67
Hepatoprotective potential of isoquercitrin against type 2 diabetes-induced hepatic injury in rats
Huang, X., He, Y., Ji, L.-L., Wang, K., Wang, Y., Chen, D., Geng, Y., Ouyang, P., & Lai, W. (2017) · Oncotarget · doi:10.18632/oncotarget.21074 · Cited by 61
Kang, Z. F., Deng, Y., Zhou, Y., Fan, R. R., Chan, J. C. N., Laybutt, D. R., Luzuriaga, J., & Xu, G. (2013) · Diabetologia · doi:10.1007/s00125-012-2776-x · Cited by 54
“Moreover, a growing body of evidence has shown that the glucose-lowering effects of GLP-1 are mediated by various mechanisms, including stimulation of glucose-dependent insulin secretion in pancreatic beta cells [1, 2], promotion of pancreatic beta cell proliferation and inhibition of beta cell apoptosis [9–11], inhib…”
BackgroundKim, M.-H., Kim, E.-H., Jung, H. S., Yang, D., Park, E.-Y., & Jun, H. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.12.005 · Cited by 58
Limbert, C., Päth, G., Jakob, F. J., & Seufert, J. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.06.016 · Cited by 62
“[35] Y.”
BackgroundSingle Dose GLP-1-Tf Ameliorates Myocardial Ischemia/Reperfusion Injury
Matsubara, M., Kanemoto, S., Leshnower, B. G., Albone, E. F., Hinmon, R., Plappert, T. A., Gorman, J. H., & Gorman, R. C. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.03.016 · Cited by 54
“GLP-1 has insulinomimetic [2] and insulinotropic [3] actions as well as antiapoptotic properties [4,5].”
Glucagon-Like Peptide-1 Regulates Cholecystokinin Production in β-Cells to Protect From Apoptosis
Linnemann, A. K., Neuman, J. C., Battiola, T. J., Wisinski, J. A., Kimple, M. E., & Davis, D. B. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1030 · Cited by 54
Exendin-4 Protects Hypoxic Islets From Oxidative Stress and Improves Islet Transplantation Outcome
Padmasekar, M., Lingwal, N., Samikannu, B., Chen, C., Sauer, H., & Linn, T. (2013) · Endocrinology · doi:10.1210/en.2012-1983 · Cited by 53
Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets
Tudurí, E., López, M., Diéguez, C., Nadal, Á., & Nogueiras, R. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.004 · Cited by 56
“10 days + STZ-treated mice, fed state [77]”
BackgroundInfluentialTang, D., Wang, Q., Burkhardt, B. R., Litherland, S. A., Atkinson, M. A., & Yang, L.-J. (2012) · Europe PMC (PubMed Central) · Cited by 66
The lean patient with type 2 diabetes: characteristics and therapy challenge
Brunetti, P. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01359.x · Cited by 56
Biswas, S. C., Buteau, J., & Greene, L. A. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9646-4 · Cited by 55
“GLP-1 acts as a growth factor for cultured b-cells through stimulation of pancreatic b-cell proliferation [11, 12], and the prevention of b-cell death [13, 14 ].”
BackgroundZhang, X., Cui, T., He, J., Wang, H., Cai, R., Popovics, P., Vidaurre, I., Sha, W., Schmid, J., Ludwig, B., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518540112 · Cited by 52
Liu, J., Hu, Y., Zhang, H., Xu, Y., & Wang, G. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.020 · Cited by 54
Kadowaki, T., Namba, M., Imaoka, T., Yamamura, A., Goto, W., Boardman, M. K., & Sowa, H. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00084.x · Cited by 50
Jonas, J., Guiot, Y., Rahier, J., & Henquin, J. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1174-9 · Cited by 53
“In this context, it is tempting to speculate that the anti-apoptotic effect of glucagonlike-peptide-1 and its analog exendin-4 in pancreatic beta cells [29, 30, 31] could be mediated, at least in part, by an increase in beta-cell HO1 expression.”
BackgroundCho, J. M., Jang, H. W., Cheon, H., Jeong, Y. T., Kim, D., Lim, Y.-M., Choi, S., Yang, E.-K., Shin, C.-Y., Son, M. H., et al. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.10.012 · Cited by 52
Lim, S. W., Jin, L. G., Jin, J., & Yang, C. W. (2016) · Scientific Reports · doi:10.1038/srep29921 · Cited by 52
Anti-incretin, Anti-proliferative Action of Dopamine on β-Cells
Maffei, A., Segal, A. M., Álvarez-Pérez, J. C., García-Ocaña, A., & Harris, P. E. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1273 · Cited by 50
Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
Wang, Q., Chen, K., Liu, R., Zhao, F., Gupta, S., Zhang, N., & Prud’homme, G. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012734 · Cited by 54
Phosphoproteins in Stress-Induced Disease
Dalton, L. E., Healey, E., Irving, J. A., & Marciniak, S. J. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-396456-4.00003-1 · Cited by 52
Bader, M., Li, Y., Tweedie, D., Shlobin, N. A., Bernstein, A., Rubovitch, V., Tovar-y-Romo, L. B., DiMarchi, R. D., Hoffer, B. J., Greig, N. H., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00356 · Cited by 48
Self-citationMacDonald, P. E., Joseph, J. W., Yau, D., Diao, J., Asghar, Z., Dai, F. F., Oudit, G. Y., Patel, M. M., Backx, P. H., & Wheeler, M. B. (2004) · Endocrinology · doi:10.1210/en.2004-0028 · Cited by 54
León, D. D. D., Farzad, C., Crutchlow, M. F., Brestelli, J. E., Tobias, J. W., Kaestner, K. H., & Stoffers, D. A. (2006) · Physiological Genomics · doi:10.1152/physiolgenomics.00156.2005 · Cited by 51
The Role of PYY in Pancreatic Islet Physiology and Surgical Control of Diabetes
Guida, C., Stephen, S., Guitton, R., & Ramracheya, R. D. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.04.005 · Cited by 49
Kwon, D. Y., Kim, Y. S., Ahn, I. S., Kim, D. S., Kang, S., Hong, S. M., & Park, S. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09178fp · Cited by 44
Tonne, J. M., Sakuma, T., Deeds, M. C., Munoz-Gomez, M., Barry, M. A., Kudva, Y. C., & Ikeda, Y. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.012591 · Cited by 48
“S1), which confirmed previous studies (Li et al., 2003; Yusta et al., 2006).”
Lavine, J. A., Kibbe, C. R., Baan, M., Sirinvaravong, S., Umhoefer, H. M., Engler, K. A., Meske, L. M., Sacotte, K. A., Erhardt, D. P., & Davis, D. B. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00159.2015 · Cited by 47
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 41
Sharma, A., Sörenby, A. K., Wernerson, A. M., Efendić, S., Kumagai‐Braesch, M., & Tibell, A. (2006) · Diabetologia · doi:10.1007/s00125-006-0251-2 · Cited by 48
“Exendin-4 has been shown to protect beta cells from apoptosis induced by these cytokines in vitro [25].”
BackgroundNovel Pharmacologic Agents for Type 2 Diabetes
Uwaifo, G. I., & Ratner, R. E. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.11.006 · Cited by 51
Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts
Du, J., Zhang, L., Wang, Z., Yano, N., Zhao, Y., Lei, W., Dubielecka, P. M., Liu, P. Y., Zhuang, S., Qin, G., et al. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00194.2015 · Cited by 45
“Antiapoptosis is regarded as one of the most important cytoprotections among the pleiotropic actions reported for GLP-1 (17, 27).”
Holz, G. G., & Chepurny, O. G. (2005) · Science's STKE · doi:10.1126/stke.2682005pe2 · Cited by 45
“Habener, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagonlike peptide-1-(7-37).”
BackgroundGLP-1 agonists in type 1 diabetes
Pettus, J., Hirsch, I. B., & Edelman, S. V. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.006 · Cited by 48
Koole, C., Savage, E. E., Christopoulos, A., Miller, L. J., Sexton, P. M., & Wootten, D. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1116 · Cited by 42
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Pleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 47
Chang, T., Tseng, H.-C., Liu, M.-W., Chang, Y., Hsieh, M.-L., & Chuang, L. (2016) · Scientific Reports · doi:10.1038/srep23403 · Cited by 48
Shimizu, S., Hosooka, T., Matsuda, T., Asahara, S., Kimura-Koyanagi, M., Kanno, A., Bartolomé, A., Etoh, H., Fuchita, M., Teruyama, K., et al. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0039 · Cited by 45
Chueire, V. B., & Muscelli, E. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000313 · Cited by 50
Tews, D., Werner, U., & Eckel, J. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2008-1042426 · Cited by 43
Pancreatic β-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs
D’Amico, E., Hui, H., Khoury, N., Mario, U. D., & Perfetti, R. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01655 · Cited by 46
Picha, K. M., Cunningham, M. R., Drucker, D. J., Mathur, A. S., Ort, T., Scully, M. S., Soderman, A. R., Spinka-Doms, T., Stojanovic-Susulic, V., Thomas, B. A., et al. (2008) · Diabetes · doi:10.2337/db07-1775 · Cited by 41
Self-citationRegenerative Medicine and Stem Cell Based Drug Discovery
Sakurada, K., McDonald, F. M., & Shimada, F. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200700724 · Cited by 43
Talbot, J., Joly, E. C., Prentki, M., & Buteau, J. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.010 · Cited by 43
Wright, E. J., Farrell, K. A., Malik, N., Kassem, M., Lewis, A. L., Wallrapp, C., & Holt, C. M. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0064 · Cited by 40
Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
Riche, D. M., East, H. E., & Riche, K. D. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31818eb721 · Cited by 44
Cox, A. R., Gottheil, S., Arany, E. J., & Hill, D. J. (2010) · Pediatric Research · doi:10.1203/pdr.0b013e3181e17c90 · Cited by 45
Li, H., Lee, C. H., Yoo, K.-Y., Choi, J. H., Park, O. K., Yan, B. C., Byun, K., Lee, B., Hwang, I. K., & Won, M.-H. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.09.040 · Cited by 39
Toyoda, K., Okitsu, T., Yamane, S., Uonaga, T., Liu, X., Harada, N., Üemoto, S., Seino, Y., & Inagaki, N. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.046 · Cited by 45
Formulary Forum: Exenatide: A New Option for the Treatment of Type 2 Diabetes
Yoo, B. K., Triller, D. M., & Yoo, D. J. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h060 · Cited by 39
Sinclair, E. M., & Drucker, D. J. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000155379.11926.e2 · Cited by 39
Self-citationGlucagon-like peptide–1 and candesartan additively improve glucolipotoxicity in pancreatic β-cells
Wang, H.-W., Mizuta, M., Saitoh, Y., Noma, K., Ueno, H., & Nakazato, M. (2011) · Metabolism · doi:10.1016/j.metabol.2010.11.004 · Cited by 38
Clinical Approaches to Preserve β-Cell Function in Diabetes
WAJCHENBERG, B. L. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_23 · Cited by 41
Kimple, M. E., Moss, J. B., Brar, H. K., Rosa, T. C., Truchan, N. A., Pasker, R. L., Newgard, C. B., & Casey, P. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.359745 · Cited by 41
A Simple Matter of Life and Death—The Trials of Postnatal Beta-Cell Mass Regulation
Tarabra, E., Pelengaris, S., & Khan, M. (2012) · International Journal of Endocrinology · doi:10.1155/2012/516718 · Cited by 40
“Moreover, GLP-1 prevents beta-cell death in mouse models of beta-cell loss, in particular, in both unstressed mice [102] and in streptozotocin-induced beta-cell toxicity [95, 120].”
BackgroundHoriuchi, H., Usami, A., Shirai, R., Harada, N., Ikushiro, S., Sakaki, T., Nakano, Y., Inui, H., & Yamaji, R. (2017) · Journal of Nutrition · doi:10.3945/jn.117.250860 · Cited by 46
The role of G protein-coupled receptor kinases in GLP-1R β-arrestin recruitment and internalisation
McNeill, S. M., Lu, J., Carino, C. M. C., Inoue, A., Zhao, P., Sexton, P. M., & Wootten, D. L. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116119 · Cited by 40
Rolin, B., Deacon, C. F., Carr, R. D., & Åhrén, B. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.05.013 · Cited by 42
Gut: A key player in the pathogenesis of type 2 diabetes?
Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J. J., Laudisio, D., Orio, F., Tirabassi, G., & Colao, A. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252712 · Cited by 37
“Administration of GLP-1 was associated with proliferative and antiapoptotic effects in both endocrine and exocrine compartments of the pancreas (Bulotta et al., 2004; Farilla et al., 2002), and significantly reduced apoptotic b cells in experimental diabetes models (Li et al., 2003).”
BackgroundType 2 Diabetes: An Expanded View of Pathophysiology and Therapy
Unger, J., & Parkin, C. G. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2152 · Cited by 42
Huang, Y., Chen, Z., Chen, Y., Guo‐Chang, M. A., Shan, J., Liu, W., & Zhou, L. (2007) · Journal of Peptide Science · doi:10.1002/psc.942 · Cited by 41
Chae, S. Y., Chun, Y. G., Lee, S., Jin, C., Lee, E. S., Lee, K. C., & Youn, Y. S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21532 · Cited by 36
Mega, C., Vala, H., Rodrigues‐Santos, P., de Oliveira, J. B. F., Teixeira, F. J., Fernandes, R., Reis, F., & Teixeira‐Lemos, E. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-42 · Cited by 39
“GLP-1, a prominent active compound of the incretin family, modulates many processes in pancreatic islet: it potentiates insulin synthesis and secretion [25], inhibits glucagon secretion [26], increases islet cell proliferation, and decreases cell apoptosis [27,28].”
BackgroundDipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Janardhan, S., & Sastry, G. N. (2014) · Current Drug Targets · doi:10.2174/1389450115666140311102638 · Cited by 39
Insulin Action in the Double Incretin Receptor Knockout Mouse
Ayala, J. E., Bracy, D. P., Hansotia, T., Flock, G., Seino, Y., Wasserman, D. H., & Drucker, D. J. (2008) · Diabetes · doi:10.2337/db07-0704 · Cited by 36
Self-citationClinical results of islet transplantation
Maffi, P., & Secchi, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.010 · Cited by 36
Yaribeygi, H., Lhaf, F., Sathyapalan, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.06.013 · Cited by 37
The importance of β-cell management in type 2 diabetes
Standl, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01360.x · Cited by 40
Seino, Y., Rasmussen, M. F., Nishida, T., & Kaku, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00103.x · Cited by 35
CNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 36
Akalestou, E., Suba, K., López–Noriega, L., Georgiadou, E., CHABOSSEAU, P. L., Gallie, A., Wretlind, A., Legido‐Quigley, C., Leclerc, I., Salem, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25423-8 · Cited by 34
Kapitza, C., Heise, T., Birman, P., Jallet, K., Ramis, J., & Balena, R. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02854.x · Cited by 33
Chyan, Y., & Chuang, L. (2007) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/187221407779814570 · Cited by 37
Voss, U., Sand, E., Hellström, P. M., & Ekblad, E. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-30 · Cited by 37
“control [for a recent review see [6]] and protection of beta-cells against cytokine-mediated apoptosis [7] have been recognized.”
BackgroundGlucagon‐like peptide‐1: modulator of β ‐cell dysfunction and death
Rondas, D., D'Hertog, W., Overbergh, L., & Mathieu, C. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12165 · Cited by 32
“In addition, islets of GLP-1R−/− mice have been shown to be more susceptible to the apoptotic effects of STZ treatment as compared to wildtype islets [79].”
BackgroundGlucagon-like peptide-1 receptor agonist stimulates mitochondrial bioenergetics in human adipocytes
Góralska, J., Śliwa, A., Gruca, A., Raźny, U., Chojnacka, M., Polus, A., Solnica, B., & Malczewska-Malec, M. (2017) · Acta Biochimica Polonica · doi:10.18388/abp.2017_1634 · Cited by 34
“GLP-1 has been also shown to prevent β-cell apoptosis in animal models of diabetes (Li et al., 2003) and glucolipotoxicity (Buteau et al., 2004).”
BackgroundProtective effect of sitagliptin against renal ischemia reperfusion injury in rats
Cengi̇z, A. N., Beytur, A., Polat, A., Şamdancı, E., Sağır, M., & Parlakpınar, H. (2015) · Renal Failure · doi:10.3109/0886022x.2015.1010991 · Cited by 32
Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., & Whitton, P. S. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.07.004 · Cited by 34
RetractedAbbas, N. A. T., & Kabil, S. L. (2017) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-017-1414-z · Cited by 32
“These findings are reminiscent of observation made in studies of the effects of GLP-1 receptor activation on β cell and neuron survival, where GLP-1R stimulation leads to inhibition of caspase activation and increased cytoprotection (Li et al. 2003; During et al. 2003).”
Li, Z., Zhou, Z., Huang, G., Hu, F., Xiang, Y., & He, L.-N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076172 · Cited by 32
Boushey, R. P., Abadir, A., Flamez, D., Baggio, L. L., Li, Y., Berger, V., Marshall, B. A., Finegood, D. T., Wang, T. C., Schuit, F. C., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01195-8 · Cited by 32
Self-citationSeino, Y., Inagaki, N., Miyahara, H., Okuda, I., Bush, M., Ye, J., Holland, M. C., JOHNSON, S. L., Lewis, E., & Nakajima, H. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.896327 · Cited by 33
Wei, Q., Sun, Y., & Zhang, J. (2012) · Peptides · doi:10.1016/j.peptides.2012.06.018 · Cited by 33
Metadata
- Authors
- Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 1
- Pages
- 471-478
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2149502431
- Cited by
- 589
- References
- 64
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 9 · 2023: 6 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 17 · 2018: 7 · 2017: 16 · 2016: 26 · 2015: 34 · 2014: 41 · 2013: 45 · 2012: 33
- FWCI
- 26.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6497 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- GLP-1 receptor, beta-cell apoptosis, exendin-4, streptozotocin, beta-cell mass, cytokine-induced apoptosis, IL-1β, TNF-α, interferon-gamma, caspase activity, GLP-1 receptor signaling, type 1 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Blood Glucose, Cell Line, Cell Survival, Cycloheximide, Cytoskeletal Proteins, Diabetes Mellitus, Experimental, Colforsin, Glucagon, Glucose Tolerance Test, Cricetinae, Insulin, Islets of Langerhans, Male, Mice, Inbred C57BL, Peptide Fragments, Peptides, Protein Precursors, Protein Synthesis Inhibitors, Streptozocin, Venoms, Signal Transduction, Trans-Activators, Cytokines, Rats, Wistar, Apoptosis, Receptors, Glucagon, Mice, Knockout, In Situ Nick-End Labeling, beta Catenin, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.